Handelsavisen
prelaunch
Companies Healthcare SMSP.NS
SM
SMSP.NS NSE (India) Pharmaceuticals

SMS Pharmaceuticals Ltd

$369,15
Open in Charts → Attach watcher ⌖
USD
Set alert
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
P/E
EV / Rev
Div yield
0,10 %
Op margin
13,4 %
ROE
10,8 %
Net margin
8,8 %
Debt / equity
0,49
Beta
52w range
Volume
Day range
Prev close
Open
Next earnings
Ex-dividend
TR 1Y
About

SMS Pharmaceuticals Ltd is a pharmaceutical company that develops, manufactures, and markets generic and branded drugs, primarily in the Indian domestic market and for export.

Business. SMS Pharmaceuticals Ltd (SMSP.NS) is a pharmaceutical company engaged in the research, development, and sale of pharmaceutical products. The firm is headquartered in India and is primarily listed on the National Stock Exchange of India. As specific operating segment and geographic breakdowns are not provided, the company is described at the industry level within the Healthcare sector. Its business model centers on product sales within the Pharmaceuticals & Medical Research industry.

Classification92 %
SectorHealthcare
Business sectorPharmaceuticals & Medical Research
IndustryPharmaceuticals
ActivityPharmaceuticals & Medical Research
Generated · model-assisted
Sell-side consensus
consensus pending
— buy— hold— sell
Avg 12m price target
Upcoming events
— missing data
See all catalysts →

At a glance

Score
not yet scored
Valuation
valuation pending
Analysts
not yet wired
Ownership
not yet wired
Profitability
10,8 %
return on equity
Quality
not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

0
  • No recent newsroom coverage mentioning SMSP.
  • Sector rotation

    Sector1D1Mvs mkt
    Materials+2,3 %+6,6 %+1,7 %
    Communication Services+2,2 %−5,5 %+1,6 %
    Energy+0,6 %+3,3 %+0,0 %
    Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %
    Information Technology+0,6 %+6,7 %+0,0 %
    Consumer Discretionary+0,4 %+7,6 %−0,2 %
    Financials−0,3 %−2,8 %−0,9 %
    Consumer Staples−0,4 %+2,5 %−1,0 %
    Real Estate−0,7 %+10,9 %−1,3 %
    Industrials−1,9 %−3,1 %−2,5 %
    Utilities−1,9 %+28,2 %−2,5 %

    Developing storylines

    No tracked sagas currently linked to SMSP.NS. Browse all sagas →

    Analysis

    AI analysis
    Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

    Opportunity

    — missing data

    Upcoming catalysts

    Scheduled public events. Informational only — not investment advice.

    • Macro
    • Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
    • Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
    • Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
    • Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
    • Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
    • Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
    • Macro & political
    • ElectionSE Swedish Election2026-09-14 · SE
    • ElectionUS U.S. Midterms2026-11-03 · US
    • ElectionFR French Legislative2027-06-01 · FR

    Pre-earnings brief

    — missing data

    Signals & dispatch

    peak dispatch · —

    Composite-score breakdown

    Synthesis

    Business

    SMS Pharmaceuticals Ltd (SMSP.NS) is a pharmaceutical company engaged in the research, development, and sale of pharmaceutical products. The firm is headquartered in India and is primarily listed on the National Stock Exchange of India. As specific operating segment and geographic breakdowns are not provided, the company is described at the industry level within the Healthcare sector. Its business model centers on product sales within the Pharmaceuticals & Medical Research industry.

    Classification92 %
    SectorHealthcare
    Business sectorPharmaceuticals & Medical Research
    IndustryPharmaceuticals
    ActivityPharmaceuticals & Medical Research
    AI synthesis
    GENERATED

    SMS Pharmaceuticals Ltd maintains a debt-to-equity ratio of 0.49, indicating a relatively conservative capital structure. The company's liquidity position is assessed as medium, with a current ratio of 1.71, suggesting it can cover short-term obligations but with limited buffer. However, the company has negative net cash after subtracting total debt, which raises concerns about its ability to meet long-term obligations without additional financing.

    The company's profitability metrics show a return on equity (ROE) of 10.81% and a return on assets (ROA) of 6.00%. These figures are in line with the industry's preferred metrics, which emphasize ROE and ROA as key indicators of financial performance. The operating margin, calculated as operating income of INR 1,046.67 million on revenue of INR 7,827.48 million, is 13.37%, which is a strong indicator of cost control and pricing power.

    The company's revenue is concentrated in a few key segments and geographic regions, with the majority of its sales coming from the domestic market. The company's exposure to international markets is limited, which may reduce diversification benefits but also insulate it from foreign exchange volatility. The company's revenue concentration in a single geographic region could pose a risk if domestic demand weakens or regulatory pressures increase.

    The company's growth trajectory is mixed. Revenue for the latest period was INR 7,827.48 million, and while the outlook for the current fiscal year is positive, the next fiscal year's growth is expected to be more moderate. The company's capital expenditure of INR 1,233.79 million indicates a focus on maintaining and expanding production capacity, which is a positive sign for long-term growth. However, the company's free cash flow is negative at INR -250.31 million, which may limit its ability to fund growth initiatives without external financing.

    The company's risk profile is characterized by medium liquidity risk and low dilution potential. The risk assessment highlights the negative net cash position as a key flag, which could necessitate additional debt or equity financing in the near term. The company has not indicated any immediate plans for share dilution, and the dilution potential is assessed as low, suggesting that the company is not currently under pressure to raise capital through equity issuance.

    Recent events and filings do not indicate any material changes in the company's operations or financial position. The company's latest financial statements and disclosures are consistent with its historical performance, and there are no indications of significant regulatory or legal challenges that would impact its operations.

    Key takeaways
    • SMS Pharmaceuticals Ltd has a conservative capital structure with a debt-to-equity ratio of 0.49.
    • The company's ROE of 10.81% and ROA of 6.00% indicate strong profitability relative to its equity and asset base.
    • Revenue is concentrated in the domestic market, which may limit diversification benefits.
    • The company's free cash flow is negative, which could constrain its ability to fund growth without external financing.
    • The company's liquidity position is assessed as medium, with a current ratio of 1.71.
    • The company has low dilution potential, suggesting no immediate need for equity financing.

    Bull / Bear case

    Generated · model-assisted
    — missing data

    In focus — financials by report

    Valuation

    Market price
    $369,15
    Market cap
    Enterprise value
    P/E
    Non-GAAP P/E
    EV / Revenue
    EV / Op income
    EV / OCF
    P / B
    P / Tangible book
    Tangible book
    $6.40B
    Net cash
    -$3.11B
    Current ratio
    1.7
    Debt / equity
    0.5
    ROA
    6.0%
    ROE
    10.8%
    Cash conversion
    118.0%
    CapEx / revenue
    -15.8%
    SBC / revenue
    Dilution ratio
    0.0%

    Revenue by segment

    Market share

    — missing data

    Business relationships

    — missing data

    Supply chain

    — missing data

    Peer comparison

    — missing data

    Market position

    Stress test

    — missing data

    Predictor forecast

    Options

    — missing data

    Short squeeze

    — missing data

    Earnings-call key lines

    — missing data

    Estimate revisions

    consensus EPS · 26-week trend
    — missing data

    Sell-side observations

    — missing data

    Themes

    — missing data

    ESG

    — missing data

    Risk factors

    Dilution riskLow
    Liquidity riskMedium
    Filing-based flags
    • Net cash is negative after subtracting total debt.

    Benchmarks vs cohort

    Op Margin13,4 %Above median
    Net Margin8,8 %Above median
    ROE10,8 %Above median
    Capex / Rev-15,8 %Bottom quartile
    D/E0,49Below median
    Cash Conv1,18Above median

    Corporate actions / M&A

    — missing data

    FX exposure

    — missing data

    Comparable transactions

    — missing data

    Derivatives & instruments

    — missing data

    Actions

    Ask Handelsavisen

    — missing data
    Data sources
    • Market data
    • Market data cache
    • Issuer disclosures
    • Public news
    • Earnings transcripts
    • Consensus estimates
    • ESG data
    How metrics are computed
    • Dilution Ratio
      (shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
    • Net Cash
      cash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
    • Capex To Revenue
      capital_expenditure / revenue
    • Return On Equity
      net_income / total_equity
    • Debt To Equity
      (short_term_debt + long_term_debt) / total_equity
    • Cash Conversion Ratio
      operating_cash_flow / net_income
    Source documents
    • SMS Pharmaceuticals Ltd Market data — financials · 2026-05-29

    Ownership & reference

    Insider activity

    — missing data

    Short positioning

    — missing data

    Geographic breakdown

    — missing data
    Listings · one canonical issuer all listings resolve to the canonical
    SMSP.NSCanonical
    NSE (India) · USD

    Intel & risk

    peak dispatch · —
    OSINT findings
    Dilution riskLow
    Liquidity riskMedium
    Net cash is negative after subtracting total debt.

    Evidence & claims

    From filings & derived data
    — missing data

    The Thread

    Everything we know, in order
    — missing data
    Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage